We set out to identify tau PET-positive (A+T+) individuals among amyloid-beta (Aβ) positive participants using plasma biomarkers.
In this cross-sectional study we assessed 234 participants across the AD continuum who were evaluated by amyloid PET with [18F]AZD4694 and tau-PET with [18F]MK6240 and measured plasma levels of total tau, pTau-181, pTau-217, pTau-231, and N-terminal tau (NTA-tau). We evaluated the performances of plasma biomarkers to predict tau positivity in Aβ+ individuals.
Highest associations with tau positivity in Aβ+ individuals were found for plasma pTau-217 (AUC [CI95%] = 0.89 [0.82, 0.96]) and NTA-tau (AUC [CI95%] = 0.88 [0.91, 0.95]). Combining pTau-217 and NTA-tau resulted in the strongest agreement (Cohen’s Kappa = 0.74, CI95% = 0.57/0.90, sensitivity = 92%, specificity = 81%) with PET for classifying tau positivity.
The potential for identifying tau accumulation in later Braak stages will be useful for patient stratification and prognostication in treatment trials and in clinical practice.
We found that in a cohort without pre-selection pTau-181, pTau-217, and NTA-tau showed the highest association with tau PET positivity.
We found that in Aβ+ individuals pTau-217 and NTA-tau showed the highest association with tau PET positivity.
Combining pTau-217 and NTA-tau resulted in the strongest agreement with the tau PET-based classification.
If you do not see content above, kindly GO TO SOURCE.
Not all publishers encode content in a way that enables republishing at Neuro.vip.
This post is Copyright: Marcel S. Woo,
Arthur C. Macedo,
Jaime Fernandez Arias,
Seyyed Ali Hosseini,
Firoza Z. Lussier,
Andrea L. Benedet,
Nicholas J. Ashton,
Thomas K. Karikari,
Hartmuth C. Kolb,
Manuel A. Friese,
Tharick A. Pascoal,
Pedro Rosa‐Neto | November 3, 2023